Enterovirus A vaccine - Sinovac Biotech

Drug Profile

Enterovirus A vaccine - Sinovac Biotech

Alternative Names: Enterovirus 71-related hand, foot and mouth disease vaccine - Sinovac Biotech; EV 71; EV71 vaccine - Sinovac

Latest Information Update: 05 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sinovac Biotech
  • Class Enterovirus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Enterovirus A infections

Most Recent Events

  • 31 Dec 2016 Launched for Enterovirus A infections (In children, In infants, Prevention) in China (IV) before December 2016
  • 04 Jan 2016 Registered for Enterovirus A infections (In children, In infants, Prevention) in China (IV) - First global approval
  • 26 Feb 2014 Immunogenecity data from the phase III PRO-EV71-3001 trial in Enterovirus infections released by Sinovac Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top